ST
PCSA icon

Spinnaker Trust’s Processa Pharmaceuticals PCSA Stock Holding History

Spinnaker Trust’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-154
Closed -$25.7K – 271
2023
Q4 		$25.7K Buy
+154
New +$34.4K ﹤0.01% 269

Other funds holding PCSA

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
MSG
Main Street Group Glen Allen, Virginia $429M AUM 34.03% 1-Year Est. Return
AF
Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return
MIM
Macroview Investment Management Bethesda, Maryland $162M AUM 22.52% 1-Year Est. Return

Spinnaker Trust's PCSA Position: Q1 2024 in Review

Spinnaker Trust sold out of Processa Pharmaceuticals (PCSA) in Q1 2024, closing a stake of 154 shares — an estimated $25.7K sold.

Spinnaker Trust first reported a position in PCSA in Q4 2023 and held it in 1 quarter. The position peaked at $25.7K in Q4 2023. 9 funds tracked by Wall St. Rank hold PCSA as of Q1 2024.

  • Spinnaker Trust reported no remaining Processa Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Spinnaker Trust sold 154 Processa Pharmaceuticals shares in Q1 2024, an estimated $25.7K.
  • Spinnaker Trust first reported a position in Processa Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Spinnaker Trust's Processa Pharmaceuticals position peaked at $25.7K in Q4 2023.
  • 9 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q1 2024.

Based on Spinnaker Trust's 13F filing for Q1 2024, filed 6 May 2024.